Publications by authors named "J Hryb"
Introduction: Diet in people with multiple sclerosis (pcMS) is of interest due to its potential benefit. The objective is to evaluate the changes in eating habits in pcEM, their opinion, sources of information, perception of effect and quality of current diet.
Methods: Cross-sectional observational study based on an online survey.
Introduction: Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been increasing along the years.
Objective: to analyze the cladribine use trend across time since its approval.
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
Front Immunol
September 2024
Introduction: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies (DMTs) and neutralization of the Omicron and Wuhan variants of SARS-COV-2.
Methods: IgG anti- SARS-COV-2 spike titer were measured in a cohort of 101 pwMS under fingolimod, dimethyl fumarate, cladribine and antiCD20, as well as 28 healthy controls (HC) were measured 6 weeks after vaccination with 2 dose (Sputnik V or AZD1222) and 3 dose (homologous or heterologous schedule). Neutralizing capacity was against Omicron (BA.
Article Synopsis
- Immunosuppressive therapies like azathioprine (AZA), mycophenolate mofetil (MMF), and rituximab (RTX) are used to prevent relapses in NMOSD, but response rates specifically in Argentina were previously unknown.
- A retrospective study analyzed 139 NMOSD patients from the RelevarEM registry, tracking their response to these treatments over a mean follow-up of 41.3 months, revealing that RTX had a significantly lower treatment failure rate compared to AZA and MMF.
- The study found treatment failures were 42.8% for AZA, 40% for MMF, and only 10.3% for RTX, indicating that higher efficacy treatments like RTX
Article Synopsis
- The study evaluated the effectiveness and safety of cladribine (CLAD) for treating relapsing-remitting multiple sclerosis in 240 patients across Argentina, focusing on clinical relapses and disease progression over 24 months.
- Results showed a significant decrease in annual relapse rates from 1.19 to 0.19, with many patients achieving no evidence of disease activity (NEDA) at both 12 months (84.2%) and 24 months (77%).
- The study also monitored lymphopenia, finding that grade 1 lymphopenia was the most common, while severe grade 4 lymphopenia was rare, suggesting CLAD is a safe treatment option.